

Commissioning Statement

Treatment	Glucosamine or Chondroitin products
For the treatment of	Any indication
Commissioning position	<p>Calderdale CCG does not routinely commission the use of glucosamine or chondroitin products</p> <p>Rationale: NICE CG 177 does not recommend glucosamine or chondroitin for use in osteoarthritis.</p>
Date effective from	29 January 2015
Policy to be reviewed by	January 2018
Background information	<p>Glucosamine is a nutritional supplement which is made from shellfish or prepared in the laboratory. It's widely available in pharmacies, health food shops and supermarkets in two preparations: glucosamine sulphate and glucosamine hydrochloride.</p> <p>Chondroitin is a nutritional supplement which is made from the cartilage of animals including cows, pigs and sharks. It can be purchased in the form of capsules often in combination with glucosamine.</p> <p>Both Glucosamine and Chondroitin have been considered as products for use in the treatment of osteoarthritis.</p> <p>The NICE Clinical Guideline entitled Osteoarthritis: Care and management in adults states: "Do not offer glucosamine or chondroitin products for the management of osteoarthritis." NICE CG 177, Oct 2014 NICE CG 177 - Feb 2014</p> <p>Scottish Medicines Consortium have considered three glucosamine products, namely; Alateris[®] (glucosamine hydrochloride), Glusartel[®] (glucosamine sulphate) & Dolenio[®] (glucosamine sulphate). None have been approved for use. In the case of Alateris[®] the committee stated:</p> <p><i>"No direct clinical trial evidence of the efficacy and safety of this specific product is available. Randomised controlled trials of other formulations of glucosamine hydrochloride indicate little or no benefit over placebo in improving symptoms in patients with osteoarthritis of the knee."</i></p>
Contact for this policy	<p>North Kirklees CCG / Gt Huddersfield CCG: Eric Power</p> <p>Wakefield CCG: Joanne Fitzpatrick</p>

	Calderdale CCG: Helen Foster
--	-------------------------------------

Date of first draft	05/11/2014
(CCG only) Comments on 1 st draft by	19/11/2014
Date of second draft	21/11/2014
Circulated to APC members	21/11/2014
Comments on second draft by	05/12/2014
Date of third draft	09/12/2014
Comments on third draft by	19/12/2014
Date of fourth draft	30/12/2014
Comments on fourth draft by	07/01/2015
For consideration at SWYAPC meeting	16/01/2015

Stakeholder views sought and noted in above process
Alignment to local priorities confirmed in above process